Bayer reported that the Chinese Food and Drug Administration (CFDA) approved Stivarga (regorafenib) tablets for the second-line treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar (sorafenib) (Press release, Bayer, DEC 13, 2017, View Source [SID1234522618]).
Adaptimmune has seen partial responses in three of the first four myxoid/round cell liposarcoma (MRCLS) patients treated with its T cells. The early data raised hopes the GlaxoSmithKline-partnered drug will be effective in multiple types of solid tumor, sending Adaptimmune shares up nearly 20%.
In 2017, GlaxoSmithKline ended its partnership with Ionis Pharmaceuticals, Inc. to develop and market inotersen and a follow-up drug for rare diseases. After reviewing its options, Ionis has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion. What makes this deal a bit unusual is that Akcea is a subsidiary of Ionis.
Personalized medicine is one step closer for consumers, thanks to tiny, implantable sensors that could give an early warning of a person's developing health problems, indicate the most effective type of exercise for an individual athlete, or even help triage wounded soldiers. That's the vision for a family of devices that scientists are now developing. They have begun marketing their first device in Europe and hope to win approval for this technology in the U.S.
Using electrochemical stimulation and robot-assisted rehabilitation techniques, researchers restore walking ability in a paraplegic rat. The study reports reorganization of neural branching in the reticular formation leads to new connections and is key to motor skill recovery.
Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the FDA has granted Rare Pediatric Disease Designation for the ABO-202 program (AAV-CLN1), an AAV-based gene therapy for the treatment of CLN1 disease (infantile and late infantile onset Batten disease).
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.